Erasca Inc (ERAS) - Total Liabilities
Based on the latest financial reports, Erasca Inc (ERAS) has total liabilities worth $67.71 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Erasca Inc - Total Liabilities Trend (2019–2025)
This chart illustrates how Erasca Inc's total liabilities have evolved over time, based on quarterly financial data. See ERAS net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Erasca Inc Competitors by Total Liabilities
The table below lists competitors of Erasca Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Nine Dragons Paper (Holdings) Limited
F:N3Y
|
Germany | €89.89 Billion |
|
Companhia Energética de Minas Gerais
MX:CIGN
|
Mexico | MX$38.45 Billion |
|
North Industries Group Red Arrow Co Ltd
SHE:000519
|
China | CN¥7.52 Billion |
|
Ajanta Pharma Limited
NSE:AJANTPHARM
|
India | Rs13.57 Billion |
|
Zhejiang Wanfeng Auto Wheel Co Ltd
SHE:002085
|
China | CN¥8.18 Billion |
|
Science Applications International Corporation Common Stock
NYSE:SAIC
|
USA | $3.68 Billion |
|
Tongcheng Travel Holdings Ltd
F:TEM
|
Germany | €19.03 Billion |
|
Americold Realty Trust
NYSE:COLD
|
USA | $5.22 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down Erasca Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ERAS company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.52 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Erasca Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Erasca Inc (2019–2025)
The table below shows the annual total liabilities of Erasca Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $70.98 Million | -10.18% |
| 2024-12-31 | $79.03 Million | +0.53% |
| 2023-12-31 | $78.61 Million | -23.72% |
| 2022-12-31 | $103.06 Million | +129.59% |
| 2021-12-31 | $44.89 Million | -81.20% |
| 2020-12-31 | $238.81 Million | +245.52% |
| 2019-12-31 | $69.12 Million | -- |
About Erasca Inc
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid … Read more